These effects were associated with danthron directly targeting IL-6R and activating the downstream SRC/RAS/MAPK signaling pathway, whereas inhibition of IL-6R or ERK abrogated these effects.<h4>Conclusion</h4>This study uncovered danthron as a novel natural small-molecule agonist of IL-6R and demonstrated its therapeutic potential in thrombocytopenia. This evidence concerns the gene SRC and Thrombocytopenia.